<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992861</url>
  </required_header>
  <id_info>
    <org_study_id>8118</org_study_id>
    <secondary_id>NCI-2013-01935</secondary_id>
    <secondary_id>8118</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01CA155454</secondary_id>
    <secondary_id>RG3114003</secondary_id>
    <nct_id>NCT01992861</nct_id>
  </id_info>
  <brief_title>MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer</brief_title>
  <official_title>MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET)
      imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI
      is a procedure in which radio waves and a powerful magnet linked to a computer are used to
      create detailed pictures of areas inside the body. PET is a procedure in which a small amount
      of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make
      detailed, computerized pictures of areas inside the body where the glucose is taken up.
      Comparing results of diagnostic procedures, such as MRI and PET, done before, during and
      after radiation and chemotherapy may help doctors predict a patient's response to treatment
      and help plan the best treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the value of MRI and PET as a non-invasive predictive assay for therapy outcome
      in cervical cancer.

      OUTLINE:

      Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients
      undergo dynamic contrast-enhanced (DCE) MRI, diffusion-weighted (DW) MRI, and magnetic
      resonance (MR) spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following
      radiation therapy completion, and fludeoxyglucose F 18 (FDG) PET/computed tomography (CT) at
      baseline, 2-2.5 weeks, and 4-5 weeks.

      After completion of study, patients are followed up at least every 3-6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 14, 2014</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant metastatic rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Clinical/pelvic examination, pap smear, other standard of care investigations as indicated by clinical findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive power of the MRI and PET/CT parameters</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Hazard ratios will be calculated. Predictive power of the heterogeneity metrics will be compared and ranked with Federation of Gynecology and Obstetrics stage, lymph node status, histology, hemoglobin level, and tumor anatomic volumes. Multivariate predictive algorithms will be derived by synergizing the predictive power of imaging metrics and clinical prognosticators for clinical translation.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma, Not Otherwise Specified</condition>
  <condition>Cervical Undifferentiated Carcinoma</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <condition>Stage IB2 Cervical Cancer</condition>
  <condition>Stage II Cervical Cancer</condition>
  <condition>Stage IIA Cervical Cancer</condition>
  <condition>Stage IIB Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage IIIA Cervical Cancer</condition>
  <condition>Stage IIIB Cervical Cancer</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <description>Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion Weighted Imaging</intervention_name>
    <description>Undergo DW MRI</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>Diffusion Weighted MRI</other_name>
    <other_name>Diffusion-Weighted Magnetic Resonance Imaging</other_name>
    <other_name>Diffusion-Weighted MR Imaging</other_name>
    <other_name>Diffusion-Weighted MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>DWI MRI</other_name>
    <other_name>DWI-MRI</other_name>
    <other_name>MR Diffusion-Weighted Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Undergo DCE MRI</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>DCE MRI</other_name>
    <other_name>DCE-MRI</other_name>
    <other_name>DYNAMIC CONTRAST ENHANCED MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopic Imaging</intervention_name>
    <description>Undergo MR spectroscopy</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>1H- Nuclear Magnetic Resonance Spectroscopic Imaging</other_name>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>MRS</other_name>
    <other_name>MRS Imaging</other_name>
    <other_name>MRSI</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage IB2-IVA epithelial carcinoma of the cervix, including squamous cell,
        adeno-, and undifferentiated carcinoma, who will undergo radiation therapy for cervical
        cancer with curative intent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed stage IB2-IVA epithelial carcinoma of the
             cervix, including squamous cell, adeno-, and undifferentiated carcinoma, and excluding
             small cell/neuroendocrine carcinoma, who will undergo radiation therapy for cervical
             cancer with curative intent

          -  Surgical staging with retroperitoneal staging and lymphadenectomy is permitted

          -  Patients who will undergo standard radiation therapy with concurrent cisplatin-based
             chemotherapy for cervical cancer

          -  Patients with no prior radiation therapy to the pelvis

          -  Patients with no contra-indications to magnetic resonance (MR) imaging

          -  Patients must have adequate renal function: glomerular filtration rate (GFR) &gt; 30
             mL/min/1.73 m^2; for the test-retest sub-study MRI, patients must have a GFR of &gt; 60
             mL/min/1.73m^2

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with small cell/neuroendocrine cervical carcinoma

          -  Patients who have received any prior pelvic radiation therapy in the area of the tumor
             that precludes the delivery of a curative dose of pelvic radiation

          -  Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm
             clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers,
             weight greater than 350 pounds, GFR &lt; 30)

          -  Major medical or psychiatric illness that, in the investigator's opinion, would
             prevent completion of treatment, completion of the study protocol, or interfere with
             follow-up

          -  Life expectancy of less than 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Mayr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew M. Harkenrider</last_name>
      <phone>708-216-2575</phone>
      <email>mharkenrider@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew M. Harkenrider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael V. Knopp</last_name>
      <phone>614-293-8315</phone>
      <email>Michael.Knopp@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael V. Knopp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina A. Mayr</last_name>
      <phone>206-598-4110</phone>
      <email>ninamayr@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Nina A. Mayr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elaine Y. Lee</last_name>
      <phone>852 2255 3307</phone>
      <email>eyplee77@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Elaine Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

